PRVB - Provention Bio: Fully Priced After Recent Run
Introduction
Provention Bio (PRVB) is a clinical stage biotech company focusing on novel therapies that target immune-mediated diseases. The company is currently focused on preventing diseases in the following fields: Celiac disease, Type-1 Diabetes (T1D), Crohn's disease, lupus, and other life-threatening viral diseases. The company's current pipeline is summarized below (page 5, 10-k):
- PRV-031 (teplizumab, anti-CD3 mAb) for the interception of T1D
- PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease
- PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease
- PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative